Literature DB >> 25442070

Effects of alendronate on osteoclast formation and activity in vitro.

Caroline A Martins1, Gabriele Leyhausen1, Joachim Volk1, Werner Geurtsen2.   

Abstract

INTRODUCTION: Root resorption is a common complication after replantation following traumatic dental avulsion. Endodontic therapy combined with local and intracanal medications aims to avoid osteoclastic activity. In such cases, the application of alendronate (ALN), a bisphosphonate widely used for the treatment of bone disorders, could be of clinical relevance. This study evaluated alendronate biocompatibility on periodontal ligament cells as well as its effects on an in vitro osteoclastogenesis model.
METHODS: Alendronate cytotoxicity (10(-3) to 10(-9) mol/L) in human periodontal ligament fibroblasts, human osteogenic sarcoma cells, and murine osteoclastic precursors (RAW 264.7) was analyzed using cell number determination, cell viability, and proliferation assays. ALN (10(-6) to 10(-12) mol/L) effects on RANKL-induced osteoclastogenesis of RAW cells were assessed by tartrate-resistant acid phosphatase (TRAP) staining and activity and real-time polymerase chain reaction.
RESULTS: ALN at higher concentrations was cytotoxic for all cell types, inhibiting significantly the proliferation of human osteogenic sarcoma cells and human periodontal ligament fibroblasts (≥10(-5) mol/L). TRAP activity and expression of the osteoclast markers TRAP and cathepsin K by RAW-derived osteoclasts decreased significantly with ALN at low concentrations, reaching the maximum effect at 10(-10) mol/L.
CONCLUSIONS: We showed that ALN at very low concentrations is an effective inhibitor of RANKL-generated osteoclasts, without causing cytotoxic effects on their precursors or periapical cells. ALN at such concentrations might be useful to prevent replacement resorption in avulsed teeth.
Copyright © 2015 American Association of Endodontists. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Alendronate; RANKL; RAW 264.7; cytotoxicity; dental avulsion; osteoclastogenesis; root resorption

Mesh:

Substances:

Year:  2014        PMID: 25442070     DOI: 10.1016/j.joen.2014.07.010

Source DB:  PubMed          Journal:  J Endod        ISSN: 0099-2399            Impact factor:   4.171


  8 in total

1.  Effects of Alendronate and Dexamethasone on Osteoclast Gene Expression and Bone Resorption in Mouse Marrow Cultures.

Authors:  Lorraine Perciliano de Faria; Giuliana Sueyoshi; Taís Carvalho de Oliveira; L Shannon Holliday; Victor E Arana-Chavez
Journal:  J Histochem Cytochem       Date:  2021-12-17       Impact factor: 2.479

2.  Inhibition of osteoclastogenesis after bisphosphonate therapy discontinuation: an in vitro approach.

Authors:  Vivian Bradaschia-Correa; Giovanna C Ribeiro-Santos; Lorraine Perciliano de Faria; Paula Rezende-Teixeira; Victor E Arana-Chavez
Journal:  J Mol Histol       Date:  2022-06-14       Impact factor: 3.156

Review 3.  Treatment of Osteoporosis, with a Focus on 2 Monoclonal Antibodies.

Authors:  Biao Chang; Qi Quan; Yunqi Li; Haixia Qiu; Jiang Peng; Ying Gu
Journal:  Med Sci Monit       Date:  2018-12-03

4.  Effects of the cathepsin K inhibitor with mineral trioxide aggregate cements on osteoclastic activity.

Authors:  Hee-Sun Kim; Soojung Kim; Hyunjung Ko; Minju Song; Miri Kim
Journal:  Restor Dent Endod       Date:  2019-04-23

5.  Alendronate inhibits triglyceride accumulation and oxidative stress in adipocytes and the inflammatory response of macrophages which are associated with adipose tissue dysfunction.

Authors:  Claudia Martini; Fernando Nicolas Sosa; Ricardo Malvicini; Natalia Pacienza; Gustavo Yannarelli; María Del C Vila
Journal:  J Physiol Biochem       Date:  2021-07-24       Impact factor: 4.158

Review 6.  Clinical impact of bisphosphonates in root canal therapy.

Authors:  Mothanna K AlRahabi; Hani M Ghabbani
Journal:  Saudi Med J       Date:  2018-03       Impact factor: 1.484

7.  Effect of 1% sodium alendronate in the non-surgical treatment of periodontal intraosseous defects: a 6-month clinical trial.

Authors:  Bernardo Carvalho Dutra; Alcione Maria Soares Dutra Oliveira; Peterson Antônio Dutra Oliveira; Flavio Ricardo Manzi; Sheila Cavalca Cortelli; Luís Otávio de Miranda Cota; Fernando Oliveira Costa
Journal:  J Appl Oral Sci       Date:  2017 May-Jun       Impact factor: 2.698

8.  The Effect of Alendronate on Osteoclastogenesis in Different Combinations of M-CSF and RANKL Growth Factors.

Authors:  Věra Hedvičáková; Radmila Žižková; Matěj Buzgo; Michala Rampichová; Eva Filová
Journal:  Biomolecules       Date:  2021-03-16
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.